Literature DB >> 3815766

Follow-up evaluation of infant paroxysmal atrial tachycardia: transesophageal study.

D W Benson, A Dunnigan, D G Benditt.   

Abstract

We report results of follow-up transesophageal electrophysiologic studies in 35 infants seven to 27 months old (mean, 12 months) in whom paroxysmal atrial tachycardia (PAT) using an accessory atrioventricular (AV) connection had been previously evaluated by transesophageal study in the first 2 months (mean, 14 days) of life. No infants were receiving antiarrhythmic drug therapy at the time of follow-up study. To evaluate AV conduction and initiate PAT, a standard transesophageal pacing protocol was used: single extrastimuli in sinus rhythm, incremental pacing to second-degree AV block, and burst pacing at cycle lengths near those resulting in second-degree AV block. If PAT was not initiated during the baseline period, the protocol was repeated during the infusion of isoproterenol and after administration of atropine. At follow-up study, PAT was reinitiated in 24 of 35 (68%) infants, six of whom had exhibited recent spontaneous recurrence of PAT. AV nodal function did not differ in those with and those without inducible PAT. However, when initial and follow-up studies were compared, changes in antegrade conduction of the accessory AV connection were observed, since only five of 10 infants with preexcitation at initial study continued to exhibit preexcitation at follow-up study (1/5 infants only after isoproterenol). Additionally, changes in retrograde conduction of the accessory AV connection were observed; the ventriculoatrial interval in PAT induced at follow-up study increased by 20 to 40 msec in eight of 24 infants and by 50 to 80 msec in five of 24 infants compared with the interval at initial study.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Year:  1987        PMID: 3815766     DOI: 10.1161/01.cir.75.3.542

Source DB:  PubMed          Journal:  Circulation        ISSN: 0009-7322            Impact factor:   29.690


  9 in total

1.  Postnatal Outcomes of Fetal Supraventricular Tachycardia: a Multicenter Study.

Authors:  Kevin A Hinkle; Shabnam Peyvandi; Corey Stiver; Stacy A S Killen; Hsin Yi Weng; Susan P Etheridge; Michael D Puchalski
Journal:  Pediatr Cardiol       Date:  2017-06-29       Impact factor: 1.655

2.  High-dose sotalol is safe and effective in neonates and infants with refractory supraventricular tachyarrhythmias.

Authors:  Jarrod D Knudson; Bryan C Cannon; Jeffrey J Kim; Brady S Moffett
Journal:  Pediatr Cardiol       Date:  2011-05-08       Impact factor: 1.655

3.  Transesophageal electropharmacologic test in a newborn with familial Wolff-Parkinson-White syndrome.

Authors:  V Colloridi; M Boscioni; N Patruno; G Pulignano; G Critelli
Journal:  Pediatr Cardiol       Date:  1990-10       Impact factor: 1.655

Review 4.  Neonatal tachycardias: an update.

Authors:  D S Kothari; J R Skinner
Journal:  Arch Dis Child Fetal Neonatal Ed       Date:  2006-03       Impact factor: 5.747

5.  Atrial flutter in the fetus and young infant: an association with accessory connections.

Authors:  J Till; C Wren
Journal:  Br Heart J       Date:  1992-01

6.  Asymptomatic Ventricular Pre-excitation: Between Sudden Cardiac Death and Catheter Ablation.

Authors:  Josep Brugada; Roberto Keegan
Journal:  Arrhythm Electrophysiol Rev       Date:  2018-03

7.  Long-term efficacy of atenolol for atrioventricular reciprocating tachycardia in children less than 5 years old.

Authors:  J K Ko; J E Ban; Y H Kim; I S Park
Journal:  Pediatr Cardiol       Date:  2003-12-04       Impact factor: 1.655

8.  Esophageal electrical cardioversion of atrial fibrillation: when esophagus gives a help to cardiologists.

Authors:  Luca Santini; Giovanni B Forleo; Francesco Romeo
Journal:  Cardiol Res Pract       Date:  2011-09-15       Impact factor: 1.866

9.  Evaluation and management of wolff-Parkinson-white in athletes.

Authors:  Ashwin L Rao; Jack C Salerno; Irfan M Asif; Jonathan A Drezner
Journal:  Sports Health       Date:  2014-07       Impact factor: 3.843

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.